Parnax Lab logo

Parnax Lab

PARNAXLAB NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹144 Cr
Volatility
High Risk
P/E Ratio
16.3
EBITDA
₹25.88 Cr
Return on Equity
13.86%
Debt to Equity
0.87
Book Value
₹82.83
52W High
₹149.5
52W Low
₹104

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

2
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company might be capitalizing the interest cost

Growth Rate

Revenue Growth
31.22% higher than 3Y
Net Income Growth
6.78% lower than 3Y
Cash Flow Change
103% higher than 3Y
ROE
3.28% lower than 3Y
ROCE
12.11% higher than 3Y
EBITDA Margin (Avg.)
-31.69% lower than 3Y

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
48.74
42.61
50.99
46.37
50.12
48.36
40.22
49.04
53.38
62.6
62.94
69.63
56.8
Expenses
42.24
37.32
45.02
40.58
41.5
41.12
35.95
42.41
45.94
54.52
56.09
64.75
52.49
Operating Profit
6.5
5.29
5.97
5.79
8.62
7.24
4.27
6.63
7.44
8.08
6.85
4.88
4.31
OPM %
13.34%
12.41%
11.71%
12.49%
17.2%
14.97%
10.62%
13.52%
13.94%
12.91%
10.88%
7.01%
7.59%
Other Income
0.24
0.22
0.1
0.25
0.11
0.95
0.19
0.43
0.18
0.63
-0.17
1.76
0.15
Interest
1.16
1.43
1.35
1.41
1.5
1.38
1.23
1.28
1.22
1.4
1.47
1.61
1.64
Depreciation
1.6
1.74
1.78
1.84
1.83
1.94
1.79
1.83
1.94
2.1
1.96
2.04
2.22
PBT
3.98
2.34
2.94
2.79
5.4
4.87
1.44
3.95
4.46
5.21
3.25
2.99
0.6
Tax %
16.33%
20.09%
25.85%
19.35%
26.3%
29.77%
16.67%
26.08%
26.46%
30.33%
16.62%
27.09%
28.33%
Net Profit
3.33
1.87
2.18
2.24
3.99
3.42
1.21
2.93
3.28
3.62
2.71
2.19
0.43
EPS in Rs
2.89
1.63
1.9
1.95
3.47
2.97
1.05
2.54
2.85
3.16
2.36
1.9
0.37
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
103
71
95
106
109
95
90
163
168
189
188
249
252
Expenses
91
61
82
95
99
89
80
140
145
165
161
221
228
Operating Profit
12
10
13
10
10
6
10
23
23
24
27
27
24
OPM %
12%
14%
14%
10%
9%
7%
11%
14%
14%
12%
14%
11%
10%
Other Income
1
1
0
1
2
1
0
0
1
1
1
2
2
Interest
4
4
5
4
4
5
5
5
5
5
5
6
6
Depreciation
3
3
4
4
4
4
5
6
7
7
7
8
8
PBT
5
3
5
3
5
-2
0
12
12
12
16
16
12
Tax %
22%
28%
22%
65%
28%
48%
350%
33%
30%
20%
26%
26%
—
Net Profit
4
3
4
1
3
-3
0
8
9
10
12
12
9
EPS in Rs
5.01
2.95
4.33
1.23
3.88
-3.42
-0.42
8.4
7.51
8.37
10.03
10.26
7.79
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
8
8
8
8
8
8
8
10
11
11
11
11
Reserves
17
19
23
24
27
24
24
38
51
60
72
84
Borrowings
41
42
39
37
42
51
59
69
55
81
70
83
Other Liabilities
17
10
15
18
17
23
15
36
28
38
37
50
Total Liabilities
83
79
86
87
95
107
106
153
145
190
190
228
Fixed Assets
36
38
47
44
51
58
60
72
77
89
88
115
CWIP
1
2
0
0
0
3
5
3
2
21
29
11
Investments
1
1
0
0
0
0
0
0
0
0
0
0
Other Assets
45
38
38
43
43
46
41
78
66
80
72
101
Total Assets
83
79
86
87
95
107
106
153
145
190
190
228
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
3
16
13
9
9
6
9
21
16
32
8
Investing
-4
-6
-10
-5
-11
-13
-7
-16
-10
-32
-16
-16
Financing
6
1
-5
-7
1
5
0
12
-14
15
-16
8
Net Cash Flow
1
-2
0
1
-1
0
0
4
-3
-1
0
0
Free Cash Flow
-4
-3
5
8
-3
-4
0
-8
11
-16
16
-9
CFO/OP
15
46
134
134
99
153
71
38
103
79
130
42
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
84
100
72
65
64
88
68
85
61
63
60
56
Inventory Days
38
64
50
45
52
76
80
73
79
94
87
90
Days Payable
51
30
48
45
44
74
46
81
53
74
72
80
Cash Conversion Cycle
71
134
74
64
72
90
102
77
86
83
75
65
Working Capital Days
16
7
-26
-8
0
-31
-66
-35
-19
-23
-24
-11
ROCE %
16%
11%
14%
11%
12%
3%
6%
17%
15%
13%
14%
14%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Parnax Lab insights

55 extracted metrics + investor summaries across FY10–FY26.

Log in — free

Shareholding Pattern

Promot.72.30%Others5.00%Public22.71%As ofJun 2026
9.41% of promoter holding pledged as of 10 Sep 2026

Documents

Frequently Asked Questions about Parnax Lab

What does Parnax Lab Ltd do?
Incorporated in 1985, Parnax Lab Ltd manufactures and exports Pharmaceutical Formulations[1]
Where is Parnax Lab Ltd (506128) listed?
Parnax Lab Ltd trades as PARNAXLAB on the NSE and under code 506128 on the BSE.
Which sector does Parnax Lab Ltd belong to?
Parnax Lab Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Parnax Lab Ltd?
Parnax Lab Ltd has a market capitalisation of ₹143.57 Cr, which places it in the Small Cap band.
What is the PE ratio of Parnax Lab Ltd?
Parnax Lab Ltd trades at a PE ratio of 16.30, against a book value of ₹82.83 per share.
What is the 52-week high and low of Parnax Lab Ltd?
Over the last 52 weeks Parnax Lab Ltd has traded between ₹104 and ₹149.5.
What is the Return on Equity (ROE) of Parnax Lab Ltd?
Parnax Lab Ltd reported a return on equity of 13.86%. Its debt-to-equity ratio is 0.87.

Company Information

Incorporated in 1985, Parnax Lab Ltd manufactures and exports Pharmaceutical Formulations[1]

Website naxparlab.com
Listed 2026-08-17
Face Value ₹ 10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/506128.md for Parnax Lab Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List